Editorial: FDA-Approved Drug Repositioning for P-Glycoprotein Overexpressing Resistant Cancer

Simple item page
dc.contributor.authorYoon, Sungpilen_ZA
dc.contributor.authorWang, Xiaojuen_Za
dc.contributor.authorVongpunsawad, Sompongen_ZA
dc.contributor.authorTromp, Gerarden_ZA
dc.contributor.authorKuivaniemi, Helenaen_ZA
dc.date.accessioned2023-04-26T09:27:29Zen_ZA
dc.date.available2023-04-26T09:27:29Zen_ZA
dc.date.issued2021-03en_ZA
dc.descriptionCITATION: Yoon S, Wang X, Vongpunsawad S, Tromp G and Kuivaniemi H (2021) Editorial: FDA-Approved Drug Repositioning for P-Glycoprotein Overexpressing Resistant Cancer. Front. Oncol. 11:632657. doi.10.3389/fonc.2021.632657en_ZA
dc.descriptionThe original publication is available at: frontiersin.orgen_ZA
dc.description.abstractAnticancer drugs are an essential part of cancer treatment. Cancer cells can, however, develop resistance to these drugs by e.g., P-glycoprotein 1 (P-gp) overexpression or accumulation of mutations in the genes part of growth signaling pathways, apoptotic pathways, or repair system. Intrinsically, metastatic cancers, advanced-stage cancers, or stem cell-like cancers are usually drug-resistant and difficult to treat using current anticancer drugs. The overexpression of P-gp, also known as multidrug resistance protein 1 (MDR1) or ATP-binding cassette sub-family B member 1 (ABCB1), is one of the well-known mechanisms of resistance to anticancer drugs. Stem cell-like cancers often overexpress P-gp on their membranes, which results in inefficient treatment using the currently available anticancer drugs (1). It is, therefore, important to investigate novel therapeutic options to treat the P-gp overexpressing drug-resistant cancer cells. Identifying the mechanisms for targeting these cancers can overcome the inefficiencies of current anticancer drugs and lead to better outcomes for patients with P-gp overexpressing cancers.en_ZA
dc.description.versionPublisher’s versionen_ZA
dc.format.extent3 pagesen_ZA
dc.identifier.citationYoon S, Wang X, Vongpunsawad S, Tromp G and Kuivaniemi H (2021) Editorial: FDA-Approved Drug Repositioning for P-Glycoprotein Overexpressing Resistant Cancer. Front. Oncol. 11:632657. doi.10.3389/fonc.2021.632657en_ZA
dc.identifier.issn2234943X (online)en_ZA
dc.identifier.otherdoi.10.3389/fonc.2021.632657en_ZA
dc.identifier.urihttp://hdl.handle.net/10019.1/126838en_ZA
dc.language.isoen_ZAen_ZA
dc.publisherFrontiers Media S.Aen_ZA
dc.rights.holderAuthors retain copyrighten_ZA
dc.subjectAntineoplastic agentsen_ZA
dc.subjectDrug resistance in cancer cellsen_ZA
dc.subjectP-gp overexpresssionen_ZA
dc.subjectMDRen_ZA
dc.subjectAnticancer drugen_ZA
dc.subjectMolecular targetingen_ZA
dc.subjectCancer -- Treatmenten_ZA
dc.subjectP-glycoproteinen_ZA
dc.titleEditorial: FDA-Approved Drug Repositioning for P-Glycoprotein Overexpressing Resistant Canceren_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
sungpil_fda_2021.pdf
Size:
210.51 KB
Format:
Adobe Portable Document Format
Description:
download article
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Articles (Molecular Biology and Human Genetics)